Source: Eur Respir J, 51 (3) 1702662; 10.1183/13993003.02662-2017



Rating:

Share or cite this content

Citations should be made in the following way:
Ignacio Blanco. A well-designed/conducted study on alpha-1 antitrypsin epidemiology not quoted. Eur Respir J, 51 (3) 1702662; 10.1183/13993003.02662-2017

Member's Comments

No comment yet.

Related content which might interest you: Czech national alpha-1 antitrypsin registry Source: Virtual Congress 2020 – COPD phenotypes Year: 2020 Pilot study for detection of alpha-1 antitrypsin deficiency in a targeted Argentinean population Source: Eur Respir J 2005; 26: Suppl. 49, 59s Year: 2005 Trends in diagnosis and clinical presentation of alpha-1 antitrypsin deficiency within an Irish population Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Rare alpha-1 antitrypsin mutations in the Irish population Source: Annual Congress 2012 - COPD inflammation and genes Year: 2012 Rare alpha-1 antitrypsin mutations in the Irish population Source: Annual Congress 2011 - Genetic and environmental risk factors for respiratory diseases Year: 2011 Characteristics of zz alpha-1 antitrypsin deficiency patients on the Irish national registry Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Implementation of screening program for alpha-1 antitrypsin deficiency in Spain Source: Annual Congress 2004 - Emphysema and oxygen therapy Year: 2004 Diagnosing alpha-1 antitrypsin deficiency in Romania - first 1000 cases tested Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020 Alpha-1 antitrypsin deficiency severity and the risk of COVID-19 Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Alpha-1 antitrypsin: functional analysis of novel variants Source: Research Seminar 2014 - Protein quality control in lung disease Year: 2014 Clinical features of alpha one antitrypsin deficiency in COPD Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes Source: Eur Respir J, 56 (6) 2001441; 10.1183/13993003.01441-2020 Year: 2020 Alpha-1 antitrypsin deficiency – a potentially fatal disease Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases Year: 2017 Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Late Breaking Abstract - Genetic diagnosis of alpha-1 antitrypsin deficiency using saliva samples Source: Virtual Congress 2020 – New tools for diagnosis of obstructive diseases Year: 2020 Safety and tolerability of aerosolized human alpha-1 antitrypsin (AAT): a phase Ia/Ib clinical study Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 COPD in individuals with the PiMZ alpha-1 antitrypsin genotype Source: Eur Respir Rev, 26 (146) 170068; 10.1183/16000617.0068-2017 Year: 2017